The Effect of AIDS Clinical Trials Group Protocol 5164 on the Time From Pneumocystis jirovecii Pneumonia Diagnosis to Antiretroviral Initiation in Routine Clinical Practice: A Case Study of Diffusion, Dissemination, and Implementation
Author(s) -
Elvin Geng,
James S. Kahn,
Olivia Chang,
C. Bradley Hare,
K. A. Christopoulos,
David J. Jones,
Maya Petersen,
Steven G. Deeks,
Diane V. Havlir,
Monica Gandhi
Publication year - 2011
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cir608
Subject(s) - medicine , pneumocystis jirovecii , pneumocystis pneumonia , clinical trial , clinical practice , protocol (science) , pneumonia , intensive care medicine , human immunodeficiency virus (hiv) , family medicine , pathology , alternative medicine
Diffusion, dissemination, and implementation of scientific evidence into routine clinical practice is not well understood. The Adult AIDS Clinical Trials Group (ACTG) Protocol 5164 showed that early antiretroviral therapy (ART; ie, within 14 days) after diagnosis of an opportunistic infection improved clinical outcomes, compared with later initiation. Subsequently, the San Francisco General Hospital (SFGH) HIV/AIDS Service performed the SFGH 5164 Initiative to disseminate and implement the findings of ACTG 5164.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom